Immune checkpoint inhibitors have activity in mesothelioma. IND.227 was a phase 2 trial (120 patients planned) comparing progression-free survival of standard platinum and pemetrexed (CP) versus CP + pembrolizumab (pembro) versus pembro. Accrual to the pembro arm was discontinued on the basis of interim analysis (IA—16 wk disease control rate). CP + pembro was tolerable, with progression-free survival similar between arms and median survival and overall response rate higher than those of CP alone (19.8 mo [95% confidence interval or CI: 8.4–41.36] versus 8.9 mo [95% CI: 5.3–12.8] and 47% [95% CI: 24%–71%] versus 19% [95% CI: 5%–42%], respectively). The subsequent phase 3 trial has completed accrual; results are expected in 2023.
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171) / Piccirillo, M. C.; Chu, Q.; Bradbury, P.; Tu, W.; Coschi, C. H.; Grosso, F.; Florescu, M.; Mencoboni, M.; Goffin, J. R.; Pagano, M.; Ciardiello, F.; Cecere, F. L.; Vincent, M.; Ferrara, R.; Dawe, D. E.; Hao, D.; Lee, C. W.; Morabito, A.; Gridelli, C.; Cavanna, L.; Iqbal, M.; Blais, N.; Leighl, N. B.; Wheatley-Price, P.; Tsao, M. -S.; Ugo, F.; El-Osta, H.; Gargiulo, P.; Gaudreau, P. -O.; Tu, D.; Sederias, J.; Brown-Walker, P.; Perrone, F.; Seymour, L.; Laurie, S. A.. - In: JOURNAL OF THORACIC ONCOLOGY. - ISSN 1556-0864. - 18:6(2023), pp. 813-819. [10.1016/j.jtho.2023.02.003]
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)
Pagano M.;Ferrara R.;Morabito A.;Perrone F.;
2023-01-01
Abstract
Immune checkpoint inhibitors have activity in mesothelioma. IND.227 was a phase 2 trial (120 patients planned) comparing progression-free survival of standard platinum and pemetrexed (CP) versus CP + pembrolizumab (pembro) versus pembro. Accrual to the pembro arm was discontinued on the basis of interim analysis (IA—16 wk disease control rate). CP + pembro was tolerable, with progression-free survival similar between arms and median survival and overall response rate higher than those of CP alone (19.8 mo [95% confidence interval or CI: 8.4–41.36] versus 8.9 mo [95% CI: 5.3–12.8] and 47% [95% CI: 24%–71%] versus 19% [95% CI: 5%–42%], respectively). The subsequent phase 3 trial has completed accrual; results are expected in 2023.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
